文献速递心力衰竭与心肌病心律失常

植入式心律转复除颤器预防高危肥厚型心肌病患者心源性猝死的国际经验

International Experience With Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in High-Risk Patients With Hypertrophic Cardiomyopathy.
PubMed 文献 · Circulation · 2026-08-25

该研究回顾性分析了全球25个中心3387例植入ICD的肥厚型心肌病患者,随访7±6年。16%患者接受至少一次恰当ICD治疗(2.6%/年),二级预防和一级预防分别为35%和15%。ICD有效终止致命性室性心动过速,HCM相关死亡率低。

要点

  • ICD恰当治疗率在二级预防为35%,一级预防为15%。
  • 一级预防患者中位首次恰当治疗时间为植入后4年,16%在10年后。
  • 独立预测因素包括不明原因晕厥、左室心尖部室壁瘤、左室收缩功能障碍和非持续性室速。

核心结论

  • 在迄今最大规模国际多中心HCM-ICD队列中,ICD终止了六分之一患者的潜在致命性室性心动过速,HCM相关死亡率低。

研究设计与样本

  • 回顾性多中心队列研究,纳入25个中心(美国8个、欧洲9个、亚洲4个、澳大利亚、非洲、墨西哥和南美各1个)1992至2024年连续3387例植入ICD的HCM患者,随访7±6年(最长32年)。

主要发现

  • 550例(16%)经历至少一次恰当ICD治疗(2.6%/年),其中二级预防86/247例(35%[6.4%/年]),一级预防464/3140例(15%[2.2%/年])。
  • 一级预防患者首次恰当治疗中位时间为植入后4年,16%在≥10年后,47%经历多次干预。
  • 独立预测因素包括不明原因晕厥、左室心尖部室壁瘤、左室收缩功能障碍和动态心电图非持续性室速。
  • 一级预防患者中2946例(94%)存活,194例(6%)死亡(0.8%/年),其中HCM相关死亡68例(0.3%/年),主要死于终末期心衰(n=43)或卒中(n=9);猝死11例(0.4%), device failures occurred in 2.4% of those with life-threatening ventricular tachyarrhythmias。
  • 10年和20年无HCM相关死亡生存率分别为97%和91%。

关键数值与推荐

  • ICD恰当治疗年发生率:总体2.6%/年,二级预防6.4%/年,一级预防2.2%/年。

临床怎么用

  • 对于高危HCM患者,ICD可有效预防心源性猝死,一级预防后需长期随访,即使10年后仍可能发生首次恰当治疗。

局限性

  • 回顾性研究设计,各中心植入标准和随访方案可能存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Implanted cardioverter-defibrillators (ICDs) have been used in patients with hypertrophic cardiomyopathy (HCM) to prevent sudden death, and have proven lifesaving for many patients. However, experience with ICD therapy has largely been derived from relatively small HCM cohorts confined to specific countries or regions of the world. Therefore, we sought to determine the effectiveness of ICDs in preventing sudden death due to life-threatening ventricular arrhythmias in a large international multicenter HCM population. METHODS: Databases from 25 HCM centers (8 in the United States, 9 in Europe, 4 in Asia, and 1 each in Australia, Africa, Mexico, and South America) were retrospectively interrogated to identify consecutive patients with HCM with ICDs (1992 to 2024) followed for 7±6 years (up to 32 years) for clinical outcomes. RESULTS: A total of 3387 patients were identified (63% men). They had a mean left ventricular thickness of 22±7 mm. The participants had received ICDs at a mean age of 47±17 years. Over follow-up, 550 patients (16%) experienced ≥1 appropriate ICD therapy (2.6%/y), including 86 of the 247 implanted for secondary prevention (35% [6.4%/y]) and 464 of the 3140 implanted for primary prevention (15% [2.2%/y]). Appropriate therapy occurred in the 464 primary prevention patients at a mean age of 49±17 years, with a median time to first appropriate therapy of 4 years after ICD implantation; 16% of these received their first appropriate therapy ≥10 years after implantation, and 47% experienced multiple interventions. Independent predictors of appropriate ICD therapy included unexplained syncope, left ventricular apical aneurysms, left ventricular systolic dysfunction, and nonsustained ventricular tachycardia on ambulatory monitoring. Of the 3140 primary prevention patients, 2946 survived (94%) and 194 died (6%) (0.8%/y), including 68 due to HCM (0.3%/y), predominantly of end-stage heart failure (n=43) or stroke (n=9). In contrast, 11 patients (0.4%) died suddenly, with device failures occurring in 2.4% of those with life-threatening ventricular tachyarrhythmias. Survival free from HCM-related mortality at 10 and 20 years was 97% and 91%, respectively. CONCLUSIONS: In this international multicenter study, the largest to date, including >3300 consecutive patients with HCM and ICDs, device therapy terminated potentially lethal ventricular tachyarrhythmias in 1 of 6 patients, with low HCM-related mortality rates for patients with ICDs. These novel data demonstrate the effectiveness of the ICD initiative, which has probably favorably altered the natural history of many patients with HCM worldwide.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Rowin EJ, Maron BJ, Siontis KC, et al. International Experience With Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in High-Risk Patients With Hypertrophic Cardiomyopathy. Circulation. 2026. PMID: 42639666. doi:10.1161/CIRCULATIONAHA.125.078597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。